CUMYL-FUBINACA

CUMYL-FUBINACA is a synthetic cannabinoid that is also a full agonist for the cannabinoid receptors, with an binding affinity of 0.58nM for CB1 and 0.21nM for CB2. It was first identified in Japan in 2014.

Chemistry

CUMYL-FUBINACA is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor with a binding affinity of 0.58nM. The chemical structure consists of a cumyl group, which is a common feature in this class of synthetic cannabinoids.

Pharmacology

CUMYL-FUBINACA acts as a full agonist with a binding affinity of 0.58nM for CB1 and 0.21nM for CB2 cannabinoid receptors. The exact pharmacokinetics of CUMYL-FUBINACA within the body is unknown.

Effects

The effects of CUMYL-FUBINACA can be potent and severe. They can include euphoria, relaxation, perception changes, and adverse effects such as nausea, vomiting, tachycardia, hypertension, and seizures. The severity of these effects is likely related to the high potency of the drug and its full agonist activity at the CB1 receptor.

Legal Status

CUMYL-FUBINACA is a controlled substance in some countries, including the United States, Japan, and some European Union countries. It is often found in synthetic cannabis products, which are illegal in many jurisdictions.

See Also

• Synthetic cannabinoids
• Cannabinoid receptor
• Indazole

CUMYL-FUBINACA Resources
Latest articles Most recent articles Ongoing trials	Wikipedia